General Inception

General Inception acts as an "igniter" or business co-founder for deep tech and life science startups. It partners with scientific founders at inception to provide domain expertise, executive talent, infrastructure resources, capital support and access to strategic partners. Its unique model accelerates the journey from idea through seed investment and beyond. With over 35 co-founded ventures since its founding in 2020—including therapeutics platforms leveraging AI-driven biological data analysis—GI has become a key player in building innovative biotech firms targeting major unmet needs in oncology, autoimmune disease and rare disorders. The recent acquisition of Enable Medicine adds advanced generative AI capabilities for drug discovery across the entire ecosystem.